December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Milestone Pharmaceuticals Inc. - Common Shares (NQ:MIST)

2.090 -0.020 (-0.95%)
Streaming Delayed Price Updated: 11:28 AM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Milestone Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 Next >
MILESTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Milestone Pharmaceuticals Inc. on Behalf of Milestone Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MIST
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Recap: Milestone Pharmaceuticals Q3 Earnings
 
Via Benzinga
Analyst Expectations for Milestone Pharmaceuticals's Future
 
Via Benzinga
Expert Ratings for Milestone Pharmaceuticals
 
Via Benzinga
Milestone Pharmaceuticals: Q1 Earnings Insights
 
Via Benzinga
Milestone Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MIST
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Milestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate
 
Via Benzinga
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The... 
Via Benzinga
Topics Stocks
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Rises Over 3%; US Home Prices Increase In October
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The... 
Via Benzinga
Topics Stocks
ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
From The Rosen Law Firm, P.A.
Via Business Wire
Why Is Heart Disease-Focused Milestone Pharmaceuticals Stock Plummeting Today?
Milestone Pharmaceuticals Inc (NASDAQ: MIST) announced Tuesday that the Company received a Refusal to File (RTF) letter from the FDA for the New Drug Application seeking approval for self-administered... 
Via Benzinga
Dow Gains Over 50 Points; Chicago Fed National Activity Index Increases For November
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.09% to 37,418.31 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million. 
Via Benzinga
Splunk, Milestone Pharmaceuticals And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! It's time to start off the trading week with a breakdown of the biggest pre-market stock movers on Monday! 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.